Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity

Vafa, Reza Golchin; Sabahizadeh, Amirreza; Mofarrah, Ramina

doi:10.1016/j.cpcardiol.2023.102350

Cited by 2 publications

(1 citation statement)

References 121 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there was no significant difference in heart failure diagnosis or mortality [133]. SGLT2 inhibitors are also proposed to have intrinsic anti-cancer effects [134].…”

Section: Managementmentioning

confidence: 99%

Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging

Scalia,

Gheyath,

Tamarappoo

et al. 2024

JCM

View full text Add to dashboard Cite

The long-term survivorship of patients diagnosed with cancer has improved due to accelerated detection and rapidly evolving cancer treatment strategies. As such, the evaluation and management of cancer therapy related complications has become increasingly important, including cardiovascular complications. These have been captured under the umbrella term “cardiotoxicity” and include left ventricular dysfunction and heart failure, acute coronary syndromes, valvular abnormalities, pericardial disease, arrhythmia, myocarditis, and vascular complications. These complications add to the burden of cardiovascular disease (CVD) or are risk factors patients with cancer treatment are presenting with. Of note, both pre- and newly developing CVD is of prognostic significance, not only from a cardiovascular perspective but also overall, potentially impacting the level of cancer therapy that is possible. Currently, there are varying recommendations and practices regarding CVD risk assessment and mitigating strategies throughout the cancer continuum. This article provides an overview on this topic, in particular, the role of cardiac imaging in the care of the patient with cancer. Furthermore, it summarizes the current evidence on the spectrum, prevention, and management of chemotherapy-related adverse cardiac effects.

show abstract

“…However, there was no significant difference in heart failure diagnosis or mortality [133]. SGLT2 inhibitors are also proposed to have intrinsic anti-cancer effects [134].…”

Section: Managementmentioning

confidence: 99%

Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging

Scalia,

Gheyath,

Tamarappoo

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Anti-Diabetic Therapies and Cancer: From Bench to Bedside

Kounatidis,

Vallianou,

Karampela

et al. 2024

Biomolecules

View full text Add to dashboard Cite

Diabetes mellitus (DM) is a significant risk factor for various cancers, with the impact of anti-diabetic therapies on cancer progression differing across malignancies. Among these therapies, metformin has gained attention for its potential anti-cancer effects, primarily through modulation of the AMP-activated protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathway and the induction of autophagy. Beyond metformin, other conventional anti-diabetic treatments, such as insulin, sulfonylureas (SUs), pioglitazone, and dipeptidyl peptidase-4 (DPP-4) inhibitors, have also been examined for their roles in cancer biology, though findings are often inconclusive. More recently, novel medications, like glucagon-like peptide-1 (GLP-1) receptor agonists, dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) agonists, and sodium-glucose co-transporter-2 (SGLT-2) inhibitors, have revolutionized DM management by not only improving glycemic control but also delivering substantial cardiovascular and renal benefits. Given their diverse metabolic effects, including anti-obesogenic properties, these novel agents are now under meticulous investigation for their potential influence on tumorigenesis and cancer advancement. This review aims to offer a comprehensive exploration of the evolving landscape of glucose-lowering treatments and their implications in cancer biology. It critically evaluates experimental evidence surrounding the molecular mechanisms by which these medications may modulate oncogenic signaling pathways and reshape the tumor microenvironment (TME). Furthermore, it assesses translational research and clinical trials to gauge the practical relevance of these findings in real-world settings. Finally, it explores the potential of anti-diabetic medications as adjuncts in cancer treatment, particularly in enhancing the efficacy of chemotherapy, minimizing toxicity, and addressing resistance within the framework of immunotherapy.

show abstract

Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity

Cited by 2 publications

References 121 publications

Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging

Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging

Anti-Diabetic Therapies and Cancer: From Bench to Bedside

Contact Info

Product

Resources

About